用户名: 密码: 验证码:    注册 | 忘记密码?
您的位置:主页 > 英语能力 > 翻译 > 笔译 > 练习材料 > 医疗 >


2014-09-04    来源:财富网    【      美国外教 在线口语培训



When it comes to treating glaucoma, the goal of eye doctors is assuring their patient don’t go blind.

That would seem relatively easy. Give them eye drops or refer them to surgery, which helps relieve what is known as intraocular pressure (IOP) inside the eye. But with current technology, it can often be difficult to measure this pressure because it fluctuates so much and those measurements have to be done in a doctor’s office.

That soon could change, thanks to a new device described in Nature Medicine.

A team of researchers from Stanford University and Bar-Ilan University in Israel has designed an implantable sensor that can be read with a smartphone camera. This allows the patient to take readings themselves and should improve the accuracy of pressure data.
美国斯坦福大学(Stanford University)和以色列巴伊兰大学(Bar-Ilan University)的研究团队设计了一款可植入式的传感器,通过智能手机摄像头就可以获得它的读数。因此患者完全可以自行读取读数,同时它也提高了眼压数据的准确性。

“We believe this self-monitoring capabilities of the implant can significantly enhance the treatment and make it significantly better for the patient,” said Bar-Ilan’s Yossi Mandel, who co-authored the paper with Ismail Araci, Baolong Su and Stephen R. Quake of Stanford.

“Today, we think we are not treating them good enough,” he added. “They come once in a while and we take a single point in time of measurement. This probably is not good enough and we know from other studies that there is large variation in the IOP. In the same day, it can vary a lot.”

Glaucoma is a group of eye diseases that in most cases produces increased pressure within the eye and affects more than 65 million people worldwide. When the eye pressure is increased, the optic nerve becomes damaged, resulting in the death of the retinal cells, degeneration of the nerve fibers and eventually permanent loss of vision.

There are several good methods to diagnosing glaucoma but only one that monitors the disease to ensure the prescribed treatments are working. Called the Goldman applanationtonometery, or GAT, the method requires that the eye be anesthetized in a physician’s office and then a plastic prism makes contact with the cornea to measure the pressure. Not only is this uncomfortable and complex but this technique has been found in several studies to be inaccurate.

“Unfortunately, the patient can’t today measure his own IOP like he would with hypertension where you can measure your own blood pressure. Glaucoma patients have to go to their physicians,” Mandel said in a phone interview. “In one study, they measured IOP over 24 hours and saw there were large variations. In about 80 percent of the patients, they changed the treatment.”

The self-monitoring device, Mandel said, is about 50 microns in diameter and a few millimeters long. Looking much like a small tube, Mandel said the device developed in Quake’s lab is implanted in the eye.

“It looks very simple,” Mandel said. “The pressure in the eye causes a shift in the position of the fluid column in the device which then can be read much like the temperature in a thermometer.”

Glaucoma experts welcomed news of the device, saying it offers several advantages over the current methods including that it reads the pressure and does it around the clock.

“If patient comes in for cataract surgery and, if at the same time you can implant the device that would allow monitoring IOP more accurately and remotely, that has a huge benefit,” Dr. Andrew Iwach, chairman of board for the Glaucoma Research Foundation and executive director Glaucoma Center of San Francisco said. He also founded the foundation’s annual event, Glaucoma 360, which brings together researchers, industry executives and philanthropist to find a cure for glaucoma.
美国青光眼研究基金会(Glaucoma Research Foundation)的董事会主席、旧金山青光眼中心常务主任安德鲁•伊瓦施表示:“如果患者做了白内障手术的话,如果在做手术的同时,你把这款设备植入进去,那么就能更精确地监测眼压,这是有巨大好处的。”伊瓦施还是青光眼基金会“青光眼360”活动的发起人,这个活动旨在召集青光眼研究专家、行业高管和慈善人士来寻找治疗青光眼的方法。

“So if you look at the risk benefit ratio the question wouldn’t be why did you put it in but why you didn’t put it in,” he said.

There is a similar device available in Europe to measure pressure around the clock called the Sensimed Triggerfish. But this contact lens sensor doesn’t measure the eye pressure directly, which makes it less accurate and, according to a 2012 study in Arch of Ophthalmol, caused blurred vision and other adverse reactions in over 80 percent of the patients.
欧洲也有一款类似的可以随时测量眼压的设备,名叫Sensimed Triggerfish。不过这款接触式镜片传感器并非直接测量眼压,导致测量结果精确度不高。另外根据《眼科学报》(Arch of Ophthalmol)2012年的一份研究显示,它会导致80%的患者出现视觉模糊和其它负作用。

Iwach said the lack of a reliable device to measure pressure in the American market has prompted a competition of sorts with at least five companies vying to be the first to get a device inserted into the eye, which transmits an electronic signal out onto the American market.

“This is an exciting a horse race,” Iwach said. “Different camps realize the first to market, the one who figures out how to do this best, is going to potentially revolutionize how we manage glaucoma and ultimately patients will be better for it.”

While showing promise to be the first, the latest device still is several years away from being commercially feasible. It has only been tested in pigs so the next step, Mandel said, is to do further research to ensure the device is safe in humans and can remain in the eye for an extended period of time.

“As scientist we are always skeptical about what we and others do,” Mandel said. “There are challenges that have to overcome but this device shows a lot of promise.”

手机上普特 m.putclub.com 手机上普特
发表评论 查看所有评论
用户名: 密码: 验证码:
  • 推荐文章
  • 资料下载
  • 讲座录音